🧠AI AnalysisCuris Outlines Q3 2026 Progress in Lead Lymphoma Clinical Program
Curis, Inc. hosted its third-quarter 2026 corporate update, reporting steady advancement in its lead primary central nervous system lymphoma program within the TakeAim Ly…